Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT203 in Patients With Cancer Cachexia
NCT06868849Phase 2Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2024
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of JMT203 in cancer cachexia, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started May 2024; status: recruiting.
02
Drugs
JMT203
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT06868849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868849.